Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an act polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances
CA 2446197 C · Owner: Bayer Innovation Gmbh · Inventors: Halle, Jorn-Peter; Goppelt, Andreas; Hof, Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of alpha 1-antichymotrypsin (ACT) polypeptides according to SEQ ID No. 1 to SEQ ID No. 4 and/or nucleic acids encoding them, or an antibody or a fragment thereof directed against the polypeptide, or of a cell which is expressing the polypeptide or a nucleic acid encoding it, for diagnosis, treatment and/or prevention of diabetesassociated and/or arterial wounds which heal poorly and for identifying pharmacologically active substances which exert an influence on the expression or function, particularly the activity of ACT.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 30, 2002 and granted December 13, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 30, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 30, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.